Western University

Scholarship@Western
Oncology Publications

Oncology Department

5-2008

Quality assurance of radiation therapy planning
systems: current status and remaining challenges.
Jacob Van Dyk
The University of Western Ontario, vandyk@uwo.ca

Follow this and additional works at: https://ir.lib.uwo.ca/oncpub
Part of the Medical Biophysics Commons, and the Oncology Commons
Citation of this paper:
Van Dyk, Jacob, "Quality assurance of radiation therapy planning systems: current status and remaining challenges." (2008). Oncology
Publications. 134.
https://ir.lib.uwo.ca/oncpub/134

Int. J. Radiation Oncology Biol. Phys., Vol. 71, No. 1, Supplement, pp. S23–S27, 2008
Copyright Ó 2008 Elsevier Inc.
Printed in the USA. All rights reserved
0360-3016/08/$–see front matter

doi:10.1016/j.ijrobp.2007.04.095

QA FOR RT SUPPLEMENT

QUALITY ASSURANCE OF RADIATION THERAPY PLANNING SYSTEMS: CURRENT
STATUS AND REMAINING CHALLENGES
JACOB VAN DYK, M.SC.*y
* Department of Physics and Engineering, London Regional Cancer Program/London Health Sciences Centre, London, ON, Canada; and
y
Departments of Oncology, Medical Biophysics, Diagnostic Imaging and Nuclear Medicine, and Physics and Astronomy,
University of Western Ontario, London, ON, Canada
Computerized radiation therapy planning systems (RTPSs) are pivotal for treatment planning. The acceptance,
commissioning, and quality control of RTPSs are uniquely complex and are described in the American Association
of Physicists in Medicine Task Group Report 53 (1998) and International Atomic Energy Agency Technical Report
Series No. 430 (2004). The International Atomic Energy Agency also developed a document and data package for
use by vendors and purchasers to aid with acceptance testing of RTPSs. This document is based on International
Electrotechnical Commission standard 62083 (2000) and describes both ‘‘type’’ tests to be performed in the factory
and ‘‘site’’ tests to be performed in the clinic. The American Association of Physicists Task Group Report 67
described benchmark tests for the validation of dose calculation algorithms. Test data are being produced with
the backing of the U.S. National Cancer Institute. However, significant challenges remain. Technology keeps evolving rapidly, thus requiring new quality assurance (QA) procedures. Intensity-modulated radiation therapy with its
use of inverse optimization has added a new dimension to QA, because the results are not intuitively obvious. New
technologies such as real-time ultrasound guidance for brachytherapy, TomoTherapy, and Cyberknife, require
their own specialized RTPSs with unique QA requirements. On-line imaging allows for the generation of dose reconstructions using image warping techniques to determine the daily dose delivered to the patient. With increasing
computer speeds, real-time reoptimization of treatment plans will become a reality. Gating technologies will require four-dimensional dose calculations to determine the actual dose delivered to tissue voxels. With these rapidly
changing technologies, it is essential that a strong QA culture is invoked in every institution implementing these
procedures and that new protocols are developed as a part of the clinical implementation process. Ó 2008 Elsevier Inc.
Quality assurance, Treatment planning, Radiation therapy planning systems.

A tremendous evolution (some would say a revolution) in
radiation oncology has occurred in recent years. These rapid
changes and enhancements have resulted from developments
in computer technology, which have allowed advancements
in diagnostic imaging and radiation therapy delivery capabilities. The result is that imaging using various procedures (e.g.,
computed tomography, positron emission tomography, single
photon emission tomography, magnetic resonance imaging,
ultrasonography) is much more readily available as a part of
the radiation therapy planning process. In addition, enhancements in computer-controlled dose delivery, along with the

use of multileaf collimators has allowed for both static
(step-and-shoot) and dynamic intensity-modulated radiation
therapy (IMRT). These new technologies have allowed for
more controlled dose delivery with greater dose gradients
and tighter margins. The net effect is that radiation oncologists
are able to prescribe greater doses while maintaining normal
tissue toxicities at acceptable levels. Central to the application
of these new technologies is the radiation therapy planning
system (RTPS).
A review of the historical development of RTPSs can be
found in a recent chapter by Van Dyk (1). The modern
RTPS allows for the use of images from various imaging modalities to aid in the definition of target volumes. It has more
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sophisticated calculation algorithms, providing more accurate
dose calculation capabilities, especially for the small beams
associated with IMRT delivery techniques. Physical or
dynamic wedge calculation capabilities are provided. Automated optimization routines used in conjunction with inverse
planning are available to help define the multileaf collimator
delivery configurations. More sophisticated dose distribution
evaluation tools are integral to automated optimization and
plan evaluation. These include the use of dose–volume constraints, display of dose–volume histograms, and the application of biologically related endpoints such as tumor control
probability, normal tissue complication probability, and the
equivalent uniform dose. For plan delivery verification, doses
can be reconstructed for specific phantom configurations, and
digitally reconstructed radiographs can be produced to compare with the portal images.
NATIONAL AND INTERNATIONAL
REPORTS ON RTPSs
Early reports on the commissioning and quality assurance
(QA) of TPSs are relatively sparse. Perhaps the forerunner of
these was a study in 1980 by McCullough and Krueger (2).
The first committee findings from Canada was reported by
Van Dyk et al. (3). An early international report on RTPSs
was published in 1987 by the International Commission on
Radiation Units and Measurements in its Report 42 (4).
That report provided a detailed description of the state-ofthe art of RTPSs of that time; however, only two pages
were devoted to QA. The American Association of Physicists
in Medicine (AAPM) Task Group Report 65 (5) provided
a detailed description of dose calculation algorithms used
by RTPSs, especially in relation to tissue inhomogeneity corrections. Recent years have seen various reports by national
and international organizations that have made recommendations regarding the commissioning and QA of RTPSs. In
1998, the AAPM published Task Group report 53 (6), giving
guidelines for users and vendors on QA for radiation therapy
planning. In 2000, the International Electrotechnical Commission produced report No. 62083 (7), identifying the safety
requirements for manufacturers of RTPSs. In 2004, both the
International Atomic Energy Agency (IAEA) (8) and the
European Society of Therapeutic Radiation Oncology (9)
published reports on the commissioning and QA of RTPSs.
Furthermore, the IAEA has recently developed a report for
acceptance testing of RTPSs (10). In 2006, The Netherlands
Commission of Radiation Dosimetry also produced a report
on QA of RTPSs (11). The IAEA Technical Report Series
No. 430 (TRS-430) (8) is perhaps the most comprehensive
of all these reports, because it attempted to be a guide for
the entire gamut of RTPSs found worldwide.
IAEA TRS-430 guidelines
The IAEA TRS-430 begins by providing a rationale for QA
of RTPSs by describing significant treatment errors that have
occurred because of the inappropriate development of QA
procedures in the clinic. Although this report is intended as
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a generic guide for the commissioning and QA of RTPSs, it
does not provide a simple or unique protocol for these tasks
because (1) internationally, a wide variety of treatment machine capabilities exists, ranging from simple 60Co machines
to complex treatment machines with multileaf collimators and
the possibility of using IMRT; (2) a wide variety of treatment
procedures are in place that are dependent on institutional
resources, patient imaging availability for treatment planning,
and treatment machine capabilities; and (3) commercial
RTPSs have a wide diversity of capabilities, ranging from relatively simple two-dimensional systems to comprehensive
three-dimensional treatment planning capabilities that make
full use of three-dimensional image data sets, possibly from
various imaging modalities. To provide guidance for this
very large scope of capabilities, the TRS-430 provides a comprehensive process that should be useful to every institution
providing radiation therapy. The report provides specific examples of the kinds of tests that need to be performed for
both commissioning and quality control (QC) purposes.
The IAEA TRS-430 does not address issues related to
acceptance testing in adequate detail. Although acceptance
testing is well-defined and a standard process for the purchase
of other radiation therapy equipment, it is not nearly as
straightforward for RTPSs. This process is complicated because the clinical implementation of an RTPS requires the
user to obtain, usually by measurement, very specific data
needed by the RTPS for proper functioning of the dose calculation algorithm for the specific radiotherapy machines used
to treat patients in the user’s clinic. To address this issue, the
IAEA has developed a new report (10) that is complete and
was published in early 2007. That report used as a guiding
document the International Electrotechnical Commission
specifications and safety requirements, Standard 62083 for
RTPSs (7), which was published in 2000 and specifically
aimed at manufacturers. The IAEA acceptance protocol requires vendors to perform and document a series of ‘‘type’’
tests using beam commissioning data supplied by the
IAEA. The beam data and added tests were based on concepts originally developed in the AAPM Report 55 (12)
and later updated by Venselaar and Welleweerd (13). Using
the beam data provided with the IAEA acceptance report, the
user selects a subset of the vendor ‘‘type’’ tests and performs
‘‘site’’ tests to ensure that the software complies with the
standards defined in the report.
Works in progress
The IAEA has initiated an additional document to be used
as a guide for the commissioning of RTPSs, although this
document is primarily intended to help clinics in the developing world, largely with simpler RTPSs. Meanwhile, using the
recommendations from AAPM Task Group report 53, the
AAPM Task Group report 67 (unpublished data: Bayouth J,
Followill D, Fraass B, et al. AAPM Radiation Therapy Committee Task Group 67: Benchmark datasets for photon beams.
2005) described the development of a series of benchmark
tests for the validation of dose calculation algorithms of
RTPSs. The measured data for these benchmark tests are
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now being produced with the financial support of the U.S.
National Cancer Institute.
REMAINING CHALLENGES
Although progress in the development of these documents,
protocols, and standards is certainly a dramatic improvement
over work done in previous decades, significant challenges
remain. Technology keeps evolving at such a rapid rate that
it is difficult to maintain up-to-date, routine, and documented
QA procedures and protocols. The following highlights some
of the outstanding challenges. Some of these challenges overlap between fundamental research to develop procedures to
improve the quality of treatment and actually addressing
QA and QC issues related to the implementation of new procedures and technologies.
Plan optimization parameters
Modern RTPSs provide automated plan optimization
capabilities using objective functions that aid in the determination of the quality of the plan. Objective functions contain
information about the desired and actual dose distribution.
The form of the objective function tends to be unique to
each commercial system. Included in the objective function
are quantities that aid in determining the importance of one
endpoint vs. another. These quantities are often known as
‘‘importance’’ factors or ‘‘weighting’’ factors or ‘‘penalty’’
factors. As a part of the planning process, the user needs to
define the dose–volume constraints for each structure of
interest, whether tumor or organ at risk. In addition, the treatment planner needs to determine the values for the importance/weighting/penalty factors. The choice of values for
these factors is dependent on the treatment site, tumor size
and location, and normal tissue type. The present practice
is for each clinic to develop its own experience on the values
for these factors based on practical experience for individual
treatment sites. The result is that the actual implementation of
automated optimization procedures is based on the very
subjective choice of these factors. One of the remaining challenges for the medical physic community is to determine
some form of standardization of both objective functions
and the relevant importance/weighting/penalty factors. It
would then be possible to generate some class solutions for
the use of these factors that can be applied to some generic
clinical situations.
Optimization in presence of uncertainties
Recent years have seen a significant number of publications addressing the uncertainties associated with the radiation therapy process, including setup, geometric, and organ
motion uncertainties. Interest is growing in accounting for
these uncertainties in the optimization process (14–18),
because of recognition that an optimized plan developed
without accounting for uncertainties could be quite different
from one developed that did account for the uncertainties.
Once implemented, these algorithms will require special
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QA procedures to test for their capabilities, limitations, and
proper functioning.
Intensity-modulated radiation therapy QA
Intensity-modulated radiation therapy, with its use of inverse optimization, has added a new dimension to QA, because the results are no longer intuitively obvious, and
manual or simple checks of the results are not possible. Consequently, individualized patient plans must be recalculated
for phantom geometries and corresponding measurements
performed on the phantom for patient-specific treatment procedures. None of the publications described in the present report addressed the QA and QC issues adequately for IMRT
planning. Recent trends are moving toward independent software packages that can calculate the monitor units using the
IMRT delivery configurations provided by the RTPS but using entirely different software. Because this software tends to
be less sophisticated than the software used by the RTPS that
developed the original plan, under certain conditions, discrepancies are likely to result between the original monitor unit
calculations done on the RTPS and those done by the QC software. The user must make an educated rationalization as to
whether the results are acceptable or whether the difference
is significant and needs additional review. Thus, two issues
evolve from this process. The first is that new QA techniques
must be developed to evaluate the software that performs the
secondary checks. The second is that the criteria of acceptability between the results of the primary software calculations
and the secondary software calculations need to be developed
such that a consistent and meaningful assessment is possible
of the comparison of these results.
For treatment planning software associated with specialized
treatment technologies (e.g., helical TomoTherapy, Cyberknife), no third-party QA software exists. Does this mean
that users must perform patient-specific dose delivery QA
measurements indefinitely or can alternative QC techniques
be developed? Thus, the challenge is to develop time-efficient
QA procedures for these specialized technologies.
Plan evaluation and radiobiological models
Modern RTPSs are also providing new plan evaluation and
optimization capabilities such as dose–volume histogram
comparisons and radiobiological evaluation. To date, the clinical application of radiobiological models remains controversial, because a general mistrust exists of their clinical
relevance and a clear understanding of their capabilities and
limitations has not been achieved (19). However, commercial
vendors of RTPSs are providing radiobiological models that
allow users to apply them to clinical situations. The challenge
is that educational materials are needed for users of these systems to describe the capabilities and limitations of both the
models themselves and the corresponding uncertainties in
the parameters used in these models, because they are generally derived from limited clinical data. One approach used by
some is to use a radiobiological tumor control probability and
normal tissue complication probability calculation for patients undergoing treatment, not as a means of optimizing
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the treatment, but rather as a QA tool. If the resulting tumor
control probability, or normal tissue complication probability,
is of concern, this would require follow-up. Thus, the radiobiologic model, at least in its early phase of clinical implementation, is not the primary calculation determining the
treatment technique but becomes a QA check. It is only after
sufficient clinical evidence is available that radiobiological
models can provide a prediction of treatment outcome accurate enough that they should come into routine clinical practice.
Dose reconstruction
Daily on-line imaging allows for the generation of dose
reconstructions using image or dose warping techniques to
determine the actual daily dose delivered to specific voxels
within the tumor and organs at risk (20–22). Furthermore,
as the speed of computers improves, real-time reoptimization
of treatment plans, using the anatomy of the day, will become
a reality in the future. Again, the challenge will be to assure the
users that both the daily imaging system and the corresponding dose reconstruction and reoptimization algorithms behave
as intended, especially when done in a real-time mode of
operation.
Four-dimensional treatment
At present, four-dimensional computed tomography and
beam gating technologies determine the specified times during the breathing cycle when the beam is to be turned on or
off. The research challenge is to ensure a consistent correlation between tumor motion and external fiducials or the references used to trigger the beam gating system. In addition,
to obtain a sense of the true dose delivered to both the target
and the organs at risk, gating technologies will require fourdimensional dose calculations to be performed during the
parts of the breathing cycle in which the beam is on. Furthermore, QA procedures will need to be developed for both the
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four-dimensional dose calculation procedures and the actual
gated delivery of the radiation dose.
Phantoms and QA tools
As a result of the increasing complexity of the radiation
therapy process, new and more specialized QA and QC
procedures are being developed. This will require new QA
tools, new phantoms, and new analysis procedures. With
highly shaped dose distributions, the trend is toward multidimensional measurement techniques with two-dimensional
detector arrays and three-dimensional gel dosimetry (for
a summary see Van Dyk [23]). Furthermore, the use of gating
and dose delivery techniques to account for breathing motion
requires the use of phantoms that include a time component.
Although technologies and QA tools are being developed, no
consistent or cohesive approach is yet available for quality
assessment of these new technologies. Thus, the challenge remains for improved QA and QC tools that are relatively inexpensive, relatively easy to use, and relatively universal to
apply.
CONCLUSION
The RTPS is at the hub of the overall radiation therapy
process. This report provides a review of the documents
produced by various working groups, both national and international, associated with QA of RTPSs. With the rapid development and on-going changes in imaging and radiation
therapy technologies, QA and QC procedures require constant redevelopment and evolution. Future directions are considered and challenges outlined. With these rapidly changing
technologies, it is essential that a strong QA culture is invoked in every institution implementing these new and advanced procedures and that new protocols are developed as
a part of the clinical implementation process.
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